

## Role of hippocalcin in mediating AB toxicity

**Author/Contributor:**

Lim, Yun-An; Giese, Maria; Shepherd, Claire; Halliday, Glenda; Kobayashi, Masaaki; Takamatsu, Ken; Staufenbiel, Matthias; Eckert, Anne; Götz, Jürgen

**Publication details:**

BBA - Biochimica et Biophysica Acta  
v. 1822  
Chapter No. 8  
pp. 1247-1257  
0006-3002 (ISSN)

**Publication Date:**

2012

**Publisher DOI:**

<http://dx.doi.org/10.1016/j.bbadis.2012.04.007>

**License:**

<https://creativecommons.org/licenses/by-nc-nd/3.0/au/>

Link to license to see what you are allowed to do with this resource.

Downloaded from <http://hdl.handle.net/1959.4/53614> in <https://unsworks.unsw.edu.au> on 2022-12-04

## Role of hippocalcin in mediating A $\beta$ toxicity

Yun-An Lim<sup>a\*</sup>, Maria Giese<sup>b</sup>, Claire Shepherd<sup>c</sup>, Glenda Halliday<sup>c</sup>, Masaaki Kobayashi<sup>d</sup>,  
Matthias Staufenbiel<sup>e</sup>, Anne Eckert<sup>b</sup>, Jürgen Götz<sup>a\*</sup>

<sup>a</sup>Alzheimer's & Parkinson's Disease Laboratory, Brain & Mind Research Institute,  
University of Sydney, 100 Mallett St, Camperdown, NSW 2050, Australia;

<sup>b</sup>Neurobiology Laboratory, Psychiatric University Clinics Basel, University of Basel,  
Wilhelm Klein-Strasse 27, 4012, Basel, Switzerland; <sup>c</sup>The Prince of Wales Medical  
Research Institute, University of New South Wales, Sydney, NSW2031, Australia;

<sup>d</sup>Department of Physiology, Toho University School of Medicine, Ohta-ku, Tokyo, Japan;

<sup>e</sup>Novartis Institutes for Biomedical Research, Neuroscience Discovery, CH-4002 Basel,  
Switzerland

\* Corresponding author: [limy@med.usyd.edu.au](mailto:limy@med.usyd.edu.au) or [juergen.goetz@sydney.edu.au](mailto:juergen.goetz@sydney.edu.au)

Author contribution: Y-AL, AE, JG designed the experiments. Y-AL and MG performed the experiments; Y-AL, AE and JG analyzed and discussed the data; Y-AL and AE performed statistics; CS, GH, MK and MS provided materials and input to discussion; and Y-AL and JG wrote the paper.

**Abstract (250 words)**

Alzheimer's disease (AD) is the most common cause of dementia. There is no cure available and the current treatments provide only limited symptomatic relief. Histopathological hallmarks of the AD brain are the amyloid-beta (A $\beta$ ) plaques and the tau-containing neurofibrillary tangles. These A $\beta$  and tau lesions do not occur at random, rather, the neurodegenerative process is stereotyped in that it is initiated in the entorhinal cortex and hippocampal formation. Interestingly, it is the latter brain area where the calcium-sensing enzyme hippocalcin is highly expressed. As calcium deregulation in the form of excitotoxicity is a well-established pathomechanism in AD, we aimed to address the putative role of hippocalcin in human AD brain and transgenic mouse models. We found that levels of hippocalcin are higher in human AD brains and in A $\beta$  plaque-forming APP23 transgenic mice compared to controls. In APP23 mice there was an inverse relationship between A $\beta$  and hippocalcin staining as those cells with the highest intracellular A $\beta$  had very low levels of hippocalcin. To determine the role of hippocalcin in A $\beta$  toxicity, we treated primary cultures derived from mice lacking hippocalcin with A $\beta$  and found that they were more susceptible to A $\beta$  toxicity than the controls. Likewise, treatment with thapsigargin and ionomycin, respectively, both of which are known to deregulate intracellular calcium levels, caused an increased toxicity in hippocampal neurons from hippocalcin knock-out mice compared to wild-type controls. Our findings suggest that hippocalcin has a neuroprotective role in AD. The data further suggest hippocalcin as a putative biomarker for AD.

## Introduction

Alzheimer's disease (AD) is the most common form of dementia, affecting approximately 26 million people worldwide [1]. Histopathologically, the AD brain is characterized by the deposition of amyloid- $\beta$  ( $A\beta$ ) plaques and tau-containing neurofibrillary tangles in the brain [2-5]. At present, there is no cure for this debilitating disease [1]. Of all structures in the brain, the hippocampus is one of the earliest to be affected in AD, reflecting the fact that it is the formation of new memories that is impaired at an early stage of disease [6, 7]. Furthermore, the hippocampus is a brain area that has been shown to be a major target of excitotoxic damage, whereby neurons die because of an excessive stimulation of glutamate receptors [8].

Hippocalcin is a protein that is highly expressed in the hippocampus [9]. It is a member of the neuronal-specific calcium sensor (NCS) family of proteins, and as such by employing a calcium-activated myristoyl switch is translocated to the plasma membrane upon binding calcium [10]. The expression pattern of hippocalcin differs from that of the other known members of the protein family, with hippocalcin being mainly expressed in the hippocampus, while the other members are mainly found in other brain regions [11]. This suggests that hippocalcin it has a unique function that is not shared by the other family members. Hippocalcin has been shown to be important for the homeostasis of intracellular calcium levels [12]. Infusion of a truncated mutant form of hippocalcin that lacks the  $Ca^{2+}$  binding domains has been shown to prevent synaptically evoked LTD (long term depression) but had no effect on LTP (long term potentiation) [13]. To better understand the function of the calcium sensor hippocalcin, knock-out mice have been generated and shown to display memory deficits in spatial recognition tasks, further suggesting that the protein plays a role in memory formation [14].

Hippocalcin has been found to exert a neuroprotective effect *in vitro*, such as in the spinal cord motor neuron-like cell line NSC-34 or the neuroblastoma cell line Neuro-2a, by interacting with NAIP (neuronal apoptosis inhibitory protein) or by promoting calcium extrusion [15, 16]. There is also histopathological evidence for a role of hippocalcin in neurodegeneration, because of the protein's localization to Lewy bodies, insoluble aggregates present in Parkinson's disease brains, which suggests that

hippocalcin may play a role in the pathogenesis of this condition [17]. In Huntington's disease, on the other hand, hippocalcin levels were found to be decreased [18]. Together, this supports the notion that hippocalcin is deregulated under neurodegenerative conditions.

The present study aimed to determine the role of hippocalcin levels in Alzheimer's disease brain and in an AD mouse model with amyloid plaque formation. We further addressed its role in A $\beta$  toxicity using primary neuronal cultures that have been established from hippocalcin knock-out and wild-type mice.

## **Material and methods**

### **Ethics statement**

Human brain tissue was obtained from the Australian Brain Bank Network's Sydney Brain Bank, with approval from the Human Ethics Review Committee of the University of Sydney. Written informed consent was obtained from donors or donors next of kin for brain donation. The animal experiments were approved by the Animal Ethics Committee (AEC) of the University of Sydney (approval number K00/1-2009/3/4914).

### **Immunofluorescence staining**

The left hemispheres of APP23 transgenic mice and age-matched wild-type littermates controls after PBS perfusion, were post-fixed in 4% paraformaldehyde overnight at 4°C and the paraformaldehyde exchanged for 70% ethanol the next day. The brains were then processed in a Shandon Excelsior processor (Thermo), followed by embedding in paraffin. 3  $\mu$ m sections were rehydrated step-wise before antigen retrieval was performed in a microwave system (Milestone) in pre-warmed Tris/EDTA at pH 9.0 for 7 minutes at 120°C and allowed to cool on the bench-top for 15 minutes. Sections were stained with 6E10 (1:500, Covance), hippocalcin (1:100) [19] and counterstained with DAPI (Invitrogen) to visualize the nuclei. Alexa-Fluor secondary antibodies (Alexa-Fluor 488

and Alexa-Fluor 555, respectively, Invitrogen) were used for detection. Fluorescent pictures of the stained sections were taken on a Zeiss LSM 710 confocal microscope.

### **Transgenic mice and protein extraction**

Six and 18 month-old transgenic APP23 mice and age-matched wild-type littermate controls [20] were transcardially perfused with 1 x PBS, followed by separation of the hemispheres. The left hemisphere was post-fixed in 4% paraformaldehyde overnight at 4°C, while the right hemisphere and the hippocampus were sub-dissected and snap frozen in liquid nitrogen for Western blotting. Protein extraction was performed on mouse hippocampal tissue using RIPA buffer (50 mM Tris, 150 mM NaCl, 0.1% SDS, 0.5% sodium deoxycholate 1% Triton-X with protease inhibitors). Tissue was sonicated on ice to obtain a homogeneous suspension. The lysates were spun down at 17,000 x g for 20 minutes at 4°C. The supernatant was retrieved and protein levels were determined using the Bradford assay. Samples were kept at -80°C until further use.

### **Human tissue and protein extraction**

Frozen human hippocampal brain tissue from the inferior temporal was homogenized in Tris buffer solution (TBS) (2.5 mL of 20 mM Tris-Cl, 5 mM EDTA, 0.02% sodium azide) containing protease inhibitors (Complete Mini, Roche Diagnostics). Homogenates were centrifuged at 17,000 x g at 4°C for 2 hours and the supernatant was retrieved to obtain the Tris buffer- soluble fraction. The pellet was re-suspended in TBS containing 2% SDS (2.5 mL of 20 mM Tris-Cl, 5 mM EDTA, 0.02% sodium azide, 2% SDS) and protease inhibitors (Complete Mini, Roche Diagnostics) and was centrifuged again at 17,000 x g at 25°C for 30 minutes to obtain the SDS-soluble fraction, containing membrane-bound, intracellular proteins. The supernatant was retrieved and protein levels were determined using the Bradford assay and kept at -80°C until needed.

## **Western blotting**

40 µg of protein was separated on 10% Tris-Tricine SDS gels as described previously to visualize Aβ [21]. Proteins were transferred onto nitrocellulose membranes (Hybond, GE Healthcare). To enable an accurate comparison between the different proteins of interest, blots were cut at positions 55, 38 and 17 kDa using the protein molecular weight ladder (Fermentas, Catalogue number: SM-1811) as reference, and blocked, in parallel, with 5% skim milk in 1 x TBST (Tris-Buffered Saline with 1% Tween 20) for an hour at room temperature. Primary antibodies were diluted in 5% milk/TBST and incubated overnight at 4°C, using the following antibodies: 6E10 (directed against 1-16 amino acid residues of Aβ, 1:1000, Covance), GAPDH (1:5000, Millipore), NeuN (1:1000, Millipore) and Hippocalcin (1:1000) [19]. Blots were washed 3 times with 1 x TBST (5 minutes wash each), and incubated with the respective alkaline phosphatase-tagged secondary antibodies for 1 hour at room temperature. The blots were again washed 3 times with 1x TBST (5 minute washes each), after which they were developed with Immobilon Chemiluminescent Alkaline Phosphatase substrate (Millipore), and detected using the VersaDoc Model 4000 CCD camera system (BioRad). Densitometric analyses were performed using the ImageJ software (NIH).

## **Primary cultures**

Primary cultures were prepared from embryonic day 16 (E16) hippocalcin-knockout and wild-type mice as described previously [22]. In brief, hippocampi and cortices were dissected and trypsinized in Hank's balanced salt solution (HBSS) with 0.0008% DNase (w/v). The preparation was gently shaken and centrifuged at 720 x g for 3 minutes at room temperature to allow the brain pieces to settle at the bottom of the tube. The supernatant was aspirated and the remaining brain tissue was triturated 30 times in plating media (10% FBS in DMEM). Cell numbers were determined using a Neubauer haemocytometer (Marienfeld, Germany). 50,000 cells were plated per well. Cultures were placed in a 5% CO<sub>2</sub> incubator at 37°C for 2 h to allow the cortical neurons to adhere to the poly-lysine pre-coated 48-well plates, after which the plating medium was removed

and replaced with Neurobasal medium supplemented with 1% (v/v) B27 supplements (Gibco), 0.01% (v/v) 200mM L-glutamine (Gibco) to minimize growth of microglia and astrocytes. Cultures were grown for 10 days in vitro (DIV) before treatment.

### **Treatment and cell viability of primary cultures**

After 10 days in vitro (DIV), primary hippocampal and cortical neurons were treated with different concentrations of Thapsigargin (Sigma), ionomycin (Sigma), A $\beta$ 42 (Bachem) or DMSO for 4 days. In addition, primary cultures were treated with A $\beta$ 42 to assess the role of hippocalcin during A $\beta$  toxicity. Cell viability was assayed using MTT as described previously [23]. Background absorbance was subtracted from raw MTT absorbance readings and resulting values were normalized against DMSO vehicle treatments.

## **Results and Discussion**

### **Levels of hippocalcin are inversely correlated with A $\beta$ in APP23 mouse brain**

Hippocalcin is a neuronal protein that is highly expressed in the hippocampus [19]. Since this brain area is one of the earliest brain structures where the degenerative process is initiated in AD, we investigated the expression pattern of hippocalcin in A $\beta$ -plaque-forming APP23 mice, an established AD mouse model [24]. The APP23 strain expresses human APP together with an AD-linked KM670/671NL double mutation (Swedish mutation) [24]. In these mice, A $\beta$  levels increase with age, and by 6 months of age, A $\beta$  plaque formation is initiated. To investigate the hippocampal expression of hippocalcin, we used 18 month-old transgenic mice and wild-type littermate controls, as at 6 months of age, there was no intracellular A $\beta$  detectable (data not shown). Sagittal sections of 18 month-old mice were co-stained for A $\beta$  (with antibody 6E10) and hippocalcin [19], and counterstained with DAPI to visualize the nucleus. Confocal microscopy revealed that wild-type CA1 pyramidal neurons uniformly showed a strong reactivity for hippocalcin, while in the APP23 hippocampus, there were two types of cells revealing an inverse relationship between hippocalcin and A $\beta$ : we found CA1 neurons that showed a strong

staining for hippocalcin (grey arrowhead), that did not stain for A $\beta$ , and neurons that showed a strong staining for A $\beta$  that were hippocalcin-negative (Figure 1). Intracellular A $\beta$  has previously been correlated with neuronal loss and has been found to be an excellent predictor for synaptic dysfunction and neuronal loss in AD [25-27]. Previously, increased levels of intracellular calcium have been found to promote the formation of oligomeric forms of A $\beta$  [28, 29]. Interestingly, increased calcium levels also promote the aggregation of  $\alpha$ -synuclein that forms aggregates in Parkinson's disease [30]. As it is established that hippocalcin protects neurons by enhancing calcium extrusion [16] the inverse relationship in hippocampal neurons expressing hippocalcin and A $\beta$  suggests that A $\beta$  may cause reductions in the calcium sensor hippocalcin preventing it from conferring neuroprotection. It is known that there are less plaques in the hippocampal formation compared to the cortex in APP23 mice, despite comparable expression levels in the two brain areas [31]. Whether this is because hippocalcin confers initial protection from plaque formation in the hippocampus, which is not available to the cortex, where hippocalcin is not expressed, remains to be determined.

### **Hippocalcin protein levels in APP23 mice is higher than wild-type control mice and increases with age**

To determine whether the presence of A $\beta$  is responsible for changes in hippocalcin levels as observed by immunohistochemistry, we performed Western blotting on protein extracts obtained from brains of 6 and 18 months-old APP23 transgenic and wild-type littermate controls. We determined NeuN levels as a loading control, as this neuronal nuclear protein has been found to correlate well with the number of viable neurons [32, 33]. We found that levels of NeuN (reflecting neuronal numbers) were significantly decreased in APP23 transgenic compared to wild-type hippocampi at both 6 and 18 months of age ( $p < 0.05$  each), reflecting the fact that the transgenic mice undergo neurodegeneration as determined previously (Figure 2A)[31, 34]. APP levels were not significantly different for both age groups in the APP23 hippocampus (Figure 2B), suggesting that their levels are not affected by aging. A $\beta$  levels however were significantly higher in 18 months-old APP23 transgenic mice compared to 6 month-olds

(Figure 2C), as reported previously [24]. Since there was only a change in A $\beta$ , but not APP levels, any putative change in hippocalcin levels can therefore be attributed to levels of A $\beta$  rather than APP in these mice. We found that hippocalcin levels were increased in 18- compared to 6 months-old APP23 transgenic mice ( $p < 0.05$ ) (Figure 2D), indicating that hippocalcin levels are increased, as is A $\beta$  (Figure 2C). In contrast, there were no significant differences in hippocalcin levels at 6 compared to 18 months in wild-type controls, further indicating that it is the AD disease state that alters hippocalcin levels (Figure 2D). Together with the immunohistochemical data, this indicates an overall increase of hippocalcin in APP mutant mice. At a cellular level there are those hippocampal neurons that massively accumulate intracellular A $\beta$  and have very low hippocalcin levels, whereas others have higher hippocalcin levels in the absence of detectable A $\beta$ . This may suggest that neurons upregulate hippocalcin to counteract the toxicity of A $\beta$  as addressed below.

### **Hippocalcin levels vary with A $\beta$ levels in human hippocampus brain samples**

To validate the findings for hippocalcin observed in the transgenic AD mouse model in human tissue, we performed Western blotting on protein extracts obtained from the human AD hippocampus and age- and gender-matched control brain samples. NeuN was again used as a loading control as it correlates well with the number of viable neurons [32, 33]. Western blotting showed that levels of A $\beta$  monomers (and trimers) were significantly higher in AD brains than controls (both  $p < 0.05$ ) (Figure 3A,B), while APP levels did not differ ( $p = 0.08$ ) (Figure 3C). Together, this confirmed that levels of A $\beta$  monomers and trimers are increased in the absence of any significant changes to APP levels, as previously observed [35, 36]. NeuN levels were significantly lower in AD brains compared to controls, reflecting the neuronal loss that characterizes AD ( $p < 0.05$ ) (Figure 1D)[37]. Interestingly, after normalizing to NeuN, hippocalcin levels in AD brains were significantly increased when compared to control samples, suggesting that hippocalcin levels are upregulated in the remaining viable neurons, possibly as a protective mechanism against A $\beta$  toxicity ( $p < 0.05$ ) (Figure 3E), since NeuN levels were previously found to be a good indicator of neuronal numbers [32] and as hippocalcin is a

neuronal protein [16, 38]. Together, our findings indicate that the surviving neurons in AD brains have higher levels of hippocalcin than neurons in healthy control brains. This suggests that hippocalcin may contribute to neuronal survival.

### **Hippocalcin knock-out neurons are more sensitive to calcium deregulation than wild-type neurons**

To better understand the putative neuroprotective role of hippocalcin in calcium deregulation, primary cortical and hippocampal neuronal cultures were obtained from embryonic day 16 (E16) hippocalcin-knockout ([14] and wild-type mice. After 10 days *in vitro* (DIV), the neurons were treated with varying concentrations of thapsigargin (Figure 4) and ionomycin (Figure 5), both of which are known to raise intracellular calcium levels although via distinct mechanisms [39, 40].

Thapsigargin has been shown to raise the intracellular calcium concentration by preventing cells from directing calcium into the endoplasmic reticulum, thereby depleting intracellular calcium stores [41], while ionomycin affects extracellular calcium transport into cells by increasing the calcium permeability of the plasma membrane [42]. We compared hippocampal and cortical cultures from wild-type and hippocalcin knockout mice and treated the cultures for 2 days with the two compounds, followed by an MTT assay to assess cell viability.

Treatment with 0.1 $\mu$ M of thapsigargin revealed that wild-type hippocampal neurons were the most resistant, with a survival rate of about 75% (Figure 4A). Wild-type cortical neurons had a survival rate of less than 25%. Hippocalcin knock-out hippocampal and cortical neurons had a survival rate of 33% and 21%, respectively (Figure 4B-D). At 1.0 $\mu$ M thapsigargin, cell viability of wild-type hippocampal neurons was about 50% (Figure 4A), while for the knockout hippocampal neurons, they were 30% (Figure 4B-D). We did not find significant differences in cell viability between wild-type and hippocalcin knock-out cortical cells (around 20% to 30%) (Figure 4C,D), which is not surprising since hippocalcin is only expressed at very low levels in the cortex [11]. Together, our findings reveal that hippocalcin protects hippocampal neurons from the toxic effects exerted by thapsigargin.

To further assess the neuroprotective effects of hippocalcin, primary hippocampal and cortical cultures from hippocalcin knockout and wild-type mice were treated with different concentrations of ionomycin. Treatment with 0.1  $\mu\text{M}$  ionomycin was not toxic to any treatment groups (Figure 5). However, at 1  $\mu\text{M}$ , ionomycin was toxic only to hippocalcin-knockout hippocampal neurons ( $p < 0.001$ ) (Figure 5B), while wild-type cortical neurons, as well as hippocalcin knock-out hippocampal and cortical neurons were spared (Figure 5A,C,D). Together, this supports the notion that calcium homeostasis is critical in determining neuronal survival. Our data indicate that hippocalcin may play an important role in the maintenance of calcium homeostasis.

### **Hippocalcin knock-out neurons are more sensitive to A $\beta$ toxicity**

Since hippocalcin levels are consistently up-regulated in human AD and in AD transgenic APP23 mice, the putative neuroprotective role of hippocalcin in A $\beta$  toxicity was further investigated by determining cell viability of primary hippocampal and cortical cultures from hippocalcin knockout and wild-type mice, after treatment them with varying concentrations of A $\beta$  (Figure 6).

Treatment with A $\beta$  showed a dose-dependent toxicity and cell viability that was decreased for all cell types by treating the cultures with A $\beta$  concentrations between 0.5 and 5  $\mu\text{M}$  ( $p < 0.05$  to  $p < 0.001$ ) (Figure 6A,C,D), except for the hippocalcin knock-out hippocampal neurons, for which at 0.5  $\mu\text{M}$  of A $\beta$ , the cells revealed already the lowest viability of all cultures (Figure 6B). At 0.5  $\mu\text{M}$  A $\beta$ , the survival rate of all cell cultures was around 65% (Figure 6A,B,D), except for hippocalcin-knockout hippocampal neurons, where it was below 55% (Figure 6B). This indicates that hippocalcin-knockout hippocampal neurons are more susceptible to A $\beta$  toxicity. However at 5  $\mu\text{M}$  A $\beta$ , the survival rates of all cell types were around 45%, obliterating any neuroprotective effects of hippocalcin.

A $\beta$  is known to exert its toxicity via a myriad of mechanisms [3]. To determine whether the toxicity observed after exposure to A $\beta$  is specific to A $\beta$  rather than being a general consequence of cell death, wild-type and hippocalcin-knockout neurons were also exposed to varying concentrations of hydrogen peroxide as a source of oxidative stress,

as well as staurosporine, a non-selective protein kinase inhibitor that exerts toxicity by interfering with many toxicity pathways [43]. Importantly, for both treatments, the viability of both hippocampal knock-out hippocampal and cortical cells did not differ from their wild-type counterparts (Figure 7), indicating that the susceptibility of hippocampal knock-out hippocampal neurons to A $\beta$  toxicity is specific. Together, the findings suggest that hippocampal has a critical function in early A $\beta$ -induced toxicity in AD.

## Conclusions

Alzheimer's disease (AD) is characterized by widespread excitotoxicity, especially in the hippocampus, one of the earliest brain structures known to degenerate in AD [44]. Hippocalcin is a neuron-specific calcium sensor protein, which is highly expressed in the hippocampus and has previously been suggested to be neuroprotective [16, 38]. In this study, we found that hippocampal levels are increased in the hippocampus of human AD and in a robust AD transgenic mouse model, indicating elevated levels of hippocampal has a protective effect in neuronal survival. We found that hippocampal levels were affected by intracellular A $\beta$  levels. Our findings suggest that neurons that are capable of up-regulating hippocampal may receive some protection, as indicated by our Western blot finding.

To investigate the neuroprotective role of hippocampal, we had treated embryonic neuronal primary cultures. In this experimental paradigm, hippocampal-knock out hippocampal cultures showed significantly more toxicity in the presence of thapsigargin and ionomycin, indicating that hippocampal plays an important neuroprotective role in calcium-related neuronal injury in the hippocampus. This has significant implications for other calcium-related disorders such as stroke and epilepsy [45]. Employing the same experimental system, we could also show that hippocampal confers neuroprotection against A $\beta$  toxicity. Collectively, our study indicates for the first time, that hippocampal levels are deregulated by A $\beta$ . They present hippocampal as a biomarker and possible therapeutic target for AD.

## References

1. Ballard, C., et al., *Alzheimer's disease*. Lancet, 2011. **377**(9770): p. 1019-31.
2. Tiraboschi, P., et al., *The importance of neuritic plaques and tangles to the development and evolution of AD*. Neurology, 2004. **62**(11): p. 1984-9.
3. Schonrock, N., et al., *MicroRNA networks surrounding APP and amyloid-beta metabolism - Implications for Alzheimer's disease*. Exp Neurol, 2011.
4. Eckert, A., K. Schmitt, and J. Gotz, *Mitochondrial dysfunction - the beginning of the end in Alzheimer's disease? Separate and synergistic modes of tau and amyloid-beta toxicity*. Alzheimers Res Ther, 2011. **3**(2): p. 15.
5. Reddy, P.H., *Role of mitochondria in neurodegenerative diseases: mitochondria as a therapeutic target in Alzheimer's disease*. CNS Spectr, 2009. **14**(8 Suppl 7): p. 8-13; discussion 16-8.
6. Waldemar, G., et al., *Recommendations for the diagnosis and management of Alzheimer's disease and other disorders associated with dementia: EFNS guideline*. Eur J Neurol, 2007. **14**(1): p. e1-26.
7. Thal, L.J., *The Alzheimer's Disease Cooperative Study in 2004*. Alzheimer Dis Assoc Disord, 2004. **18**(4): p. 183-5.
8. Alberdi, E., et al., *Amyloid beta oligomers induce Ca<sup>2+</sup> dysregulation and neuronal death through activation of ionotropic glutamate receptors*. Cell Calcium, 2010. **47**(3): p. 264-72.
9. Takamatsu, K. and T. Noguchi, *Hippocalcin: a calcium-binding protein of the EF-hand superfamily dominantly expressed in the hippocampus*. Neurosci Res, 1993. **17**(4): p. 291-5.
10. Kobayashi, M., et al., *Myristoylation of hippocalcin is linked to its calcium-dependent membrane association properties*. J Biol Chem, 1993. **268**(25): p. 18898-904.
11. Saitoh, S., et al., *Expression of hippocalcin in the developing rat brain*. Brain Res Dev Brain Res, 1994. **80**(1-2): p. 199-208.
12. Jo, J., et al., *Muscarinic receptors induce LTD of NMDAR EPSCs via a mechanism involving hippocalcin, AP2 and PSD-95*. Nat Neurosci, 2010. **13**(10): p. 1216-24.

13. Palmer, C.L., et al., *Hippocalcin functions as a calcium sensor in hippocampal LTD*. *Neuron*, 2005. **47**(4): p. 487-94.
14. Kobayashi, M., et al., *Hippocalcin-deficient mice display a defect in cAMP response element-binding protein activation associated with impaired spatial and associative memory*. *Neuroscience*, 2005. **133**(2): p. 471-84.
15. Mercer, E.A., et al., *NAIP interacts with hippocalcin and protects neurons against calcium-induced cell death through caspase-3-dependent and -independent pathways*. *EMBO J*, 2000. **19**(14): p. 3597-607.
16. Masuo, Y., et al., *Hippocalcin protects hippocampal neurons against excitotoxin damage by enhancing calcium extrusion*. *Neuroscience*, 2007. **145**(2): p. 495-504.
17. Nagao, M. and H. Hayashi, *Mixed lineage kinase 2 and hippocalcin are localized in Lewy bodies of Parkinson's disease*. *J Neurol Sci*, 2009. **281**(1-2): p. 51-4.
18. Rudinskiy, N., et al., *Diminished hippocalcin expression in Huntington's disease brain does not account for increased striatal neuron vulnerability as assessed in primary neurons*. *J Neurochem*, 2009. **111**(2): p. 460-72.
19. Furuta, Y., et al., *Age-related changes in expression of hippocalcin and NVP2 in rat brain*. *Neurochem Res*, 1999. **24**(5): p. 651-8.
20. Sturchler-Pierrat, C., et al., *Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology*. *Proc Natl Acad Sci U S A*, 1997. **94**(24): p. 13287-92.
21. Schagger, H., *Tricine-SDS-PAGE*. *Nat Protoc*, 2006. **1**(1): p. 16-22.
22. Lim, Y.A., et al., *Human but not rat amylin shares neurotoxic properties with Abeta42 in long-term hippocampal and cortical cultures*. *FEBS Lett*, 2008. **582**(15): p. 2188-94.
23. Lim, Y.A., et al., *Abeta and human amylin share a common toxicity pathway via mitochondrial dysfunction*. *Proteomics*, 2010. **10**(8): p. 1621-33.
24. Bornemann, K.D. and M. Staufenbiel, *Transgenic mouse models of Alzheimer's disease*. *Ann N Y Acad Sci*, 2000. **908**: p. 260-6.
25. Christensen, D.Z., et al., *Transient intraneuronal A beta rather than extracellular plaque pathology correlates with neuron loss in the frontal cortex of APP/PS1KI mice*. *Acta Neuropathol*, 2008. **116**(6): p. 647-55.


26. Wirths, O., et al., *Intraneuronal APP/A beta trafficking and plaque formation in beta-amyloid precursor protein and presenilin-1 transgenic mice*. *Brain Pathol*, 2002. **12**(3): p. 275-86.
27. Bayer, T.A. and O. Wirths, *Intracellular accumulation of amyloid-Beta - a predictor for synaptic dysfunction and neuron loss in Alzheimer's disease*. *Front Aging Neurosci*, 2010. **2**: p. 8.
28. Itkin, A., et al., *Calcium ions promote formation of amyloid beta-peptide (1-40) oligomers causally implicated in neuronal toxicity of Alzheimer's disease*. *PLoS One*, 2011. **6**(3): p. e18250.
29. Chromy, B.A., et al., *Self-assembly of A beta(1-42) into globular neurotoxins*. *Biochemistry*, 2003. **42**(44): p. 12749-60.
30. Nath, S., et al., *Raised calcium promotes alpha-synuclein aggregate formation*. *Mol Cell Neurosci*, 2011. **46**(2): p. 516-26.
31. Calhoun, M.E., et al., *Neuron loss in APP transgenic mice*. *Nature*, 1998. **395**(6704): p. 755-6.
32. Ito, D., et al., *Enhanced expression of Iba1, ionized calcium-binding adapter molecule 1, after transient focal cerebral ischemia in rat brain*. *Stroke*, 2001. **32**(5): p. 1208-15.
33. Landshamer, S., et al., *Bid-induced release of AIF from mitochondria causes immediate neuronal cell death*. *Cell Death Differ*, 2008. **15**(10): p. 1553-63.
34. Bondolfi, L., et al., *Amyloid-associated neuron loss and gliogenesis in the neocortex of amyloid precursor protein transgenic mice*. *J Neurosci*, 2002. **22**(2): p. 515-22.
35. Nordstedt, C., et al., *Alzheimer beta/A4 amyloid precursor protein in human brain: aging-associated increases in holoprotein and in a proteolytic fragment*. *Proc Natl Acad Sci U S A*, 1991. **88**(20): p. 8910-4.
36. Teipel, S.J., et al., *Development of Alzheimer-disease neuroimaging-biomarkers using mouse models with amyloid-precursor protein-transgene expression*. *Prog Neurobiol*, 2011.

37. Brun, A. and E. Englund, *Regional pattern of degeneration in Alzheimer's disease: neuronal loss and histopathological grading*. *Histopathology*, 2002. **41**(3A): p. 40-55.
38. Paterlini, M., et al., *Expression of the neuronal calcium sensor protein family in the rat brain*. *Neuroscience*, 2000. **99**(2): p. 205-16.
39. Rogers, T.B., et al., *Use of thapsigargin to study Ca<sup>2+</sup> homeostasis in cardiac cells*. *Biosci Rep*, 1995. **15**(5): p. 341-9.
40. Takei, N. and Y. Endo, *Ca<sup>2+</sup> ionophore-induced apoptosis on cultured embryonic rat cortical neurons*. *Brain Res*, 1994. **652**(1): p. 65-70.
41. Lytton, J., M. Westlin, and M.R. Hanley, *Thapsigargin inhibits the sarcoplasmic or endoplasmic reticulum Ca-ATPase family of calcium pumps*. *J Biol Chem*, 1991. **266**(26): p. 17067-71.
42. Fasolato, C. and T. Pozzan, *Effect of membrane potential on divalent cation transport catalyzed by the "electroneutral" ionophores A23187 and ionomycin*. *J Biol Chem*, 1989. **264**(33): p. 19630-6.
43. Karaman, M.W., et al., *A quantitative analysis of kinase inhibitor selectivity*. *Nat Biotechnol*, 2008. **26**(1): p. 127-32.
44. Palop, J.J., J. Chin, and L. Mucke, *A network dysfunction perspective on neurodegenerative diseases*. *Nature*, 2006. **443**(7113): p. 768-73.
45. Sun, D.A., et al., *Long-lasting alterations in neuronal calcium homeostasis in an in vitro model of stroke-induced epilepsy*. *Cell Calcium*, 2004. **35**(2): p. 155-63.

## Figure legends

### Figure 1

Confocal fluorescence analysis of 18 months-old A $\beta$ -plaque-forming APP23 and wild-type littermate controls (WT). Paraffin-embedded sections were stained with antibodies directed against A $\beta$  (6E10; green), hippocalcin (Hc; red) and DAPI (nuclear). Neurons that have high intracellular accumulation of A $\beta$  have very low hippocalcin staining (white arrowhead), while neurons that have high hippocalcin levels have no detectable intracellular A $\beta$  staining (grey arrowhead). Scale bar, 50  $\mu$ m.




### Figure 2

Western blotting of 6 and 18 months-old APP23 transgenic mice (A). There is significantly lower neuronal numbers as measured by NeuN levels between wild-type and transgenic mice at both ages (B), indicating neuronal degeneration. APP levels remain


unchanged between 6 and 18 month-old APP transgenics (C), while A $\beta$  levels are significantly higher in 18 month-old when compared to 6 month-old transgenic mice (D). Hippocalcin levels are significantly increased from 6 to 18 months of age in the transgenic animals (E). (\*, p<0.05; \*\*,p<0.01)

Lim et al., Figure 2



**Figure 3**

Western blot analysis of human AD and control (CTL) samples (A). Neuronal numbers are significantly decreased in AD samples when compared to CTL samples (B). APP levels are comparable between AD and CTL brains (C), while there is significantly higher levels of A $\beta$  monomers and trimers in the AD brains when compared to the CTL samples (D,E). Hippocalcin levels are significantly higher in the AD brain compared to CTL samples (F). (\*, p<0.05).



**Figure 4**

MTT assay to determine cell viability after thapsigargin treatment of wild-type and hippocalcin knock-out cortical and hippocampal cultures. Wild-type hippocampal cultures were the most resistant to thapsigargin toxicity and treatment with 0.1  $\mu$ M and 1.0  $\mu$ M thapsigargin resulted in cell viabilities of 75% and 50% respectively (A). At the same concentrations, hippocalcin knock-out hippocampal cultures had a survival rate of 33% and 30%. (B) Wild-type and hippocalcin knock-out cortical cultures were not significantly different, with cell survival rates all at around 20% (C,D). (\*\*,  $p < 0.01$ ; \*\*\*,  $p < 0.001$ , #,  $p < 0.05$ )

Figure 4

Lim et al., Figure 4




Figure 5

MTT assay for cell viability after ionomycin treatment of wild-type (A,C) and hippocalcin knock-out (B,D) cortical (C,D) and hippocampal cultures (A,B). Ionomycin treatment was not toxic to all neuronal preparations except for hippocalcin knock-out hippocampal neurons (cell survival ~70%, 5B). (\*\*\*,  $p < 0.001$ ).

Figure 5

Lim et al., Figure 5





Figure 6

MTT assay for cell viability after A $\beta$ 42 treatment of wild-type (A,C) and hippocalcin knock-out (B,D) cortical (C,D) and hippocampal cultures (A,B). A $\beta$ 42 treatment induced significant cell toxicity in all neuronal cultures. Treatment with A $\beta$ 42 at 0.5  $\mu$ M led to a survival rate of 65% in wild-type hippocampal neurons (A), 54% in hippocalcin knock-out neurons (B), and 63% in wild-type and hippocalcin knock-out cortical neurons (C,D). At 5  $\mu$ M, cell viabilities of all neuronal preparations were below 50%. (\*\*, p < 0.01; \*\*\*, p < 0.001; #, p < 0.05; ###, p < 0.001).



**Figure 7**

MTT assay for cell viability after hydrogen peroxide ( $H_2O_2$ ) and staurosporine (stau) treatments of wild-type (A,C) and hippocampin knock-out (B,D) cortical (C,D) and hippocampal cultures (A,B).. Cell viabilities of hippocampin knock-out neurons were not significantly different from the wild-type neuronal preparations after exposure to  $H_2O_2$  and staurosporine, indicating that hippocampin knock-out neurons are not selectively sensitive to toxic effects exerted by  $H_2O_2$  and staurosporine.

Lim et al., Figure 7

